Member Info for TorquayFan

You are waxing lyrical today ! I'm afraid I have to challenge you a little even though I don't have time to reply to all the points. I wasn't able to see those documentaries btw but I am happy with what I have learned from those who did.

Re. City Financial - remember they were supporting Scancell by holding shares for many years during which Vulpes had declined to be involved. But I'm delighted that Vulpes are in now, of course.

This is rather OTT is it not ? "We seem to be rising, on a crest of a wave, the science and timing is converging into us, at such a perfect time . . '' The crest of the wave was 64p I believe and we stand at a ridculous 1/8 th of that now. Why is now the perfect time ? Anytime would have been OK by me.

Then, ''our beliefs can make us fly''. Really ?
And ''Where can we go?? Phew it is frightening.'' Please explain that.

Sorry to rock your boat C7 but, crikey !
Nice weekend to you - long drive tomorrow and ATB.

''Yes, hard to get your head around how quickly the whole immunotherapy field is advancing. Have also read about the possibility of combining CAR T with PD-1 Checkpoint inhibitors in solid tumours to help overcome the immunosuppressive tumour environment. Could you imagine CAR T, combined with a vaccine, combined with PD-1 inhibitor? ''

Thanks to Gooosed and Berm - interesting stuff. One wonders about costs and side effects, but Immunotherapy IS coming up with lots of answers . . .

Nicely on topic . . . . CAR-T and cancer vaccines :-

''Among mice given the booster shot after CAR-T infusion, 60% experienced a complete response for a variety of tumors including glioblastoma, breast and melanoma. In contrast, barely anything happened to those given just the cell therapy. It represents a twist to the once-hot — but elusive — cancer vaccine approach, whose premise is to induce an immune attack on tumor cells. It also promises to solve the durability problem of CAR-T that many researchers have highlighted.''

"“If we take the animals that appear to be cured and we rechallenge them with tumor cells, they will reject all of them,” Irvine said in an interview with MIT News."

https://endpts.com/supercharging-car-t-with-cancer-vaccine-mit-team-spotlights-some-new-tech-underpinning-darrell-irvines-startup/

Re. GBP 3 billion - that's what it needs to take Moditope 1 and 2 through to full potential. I look forward to watching that happen. ATB

Just caught up with your 3 Wednesday posts re. Moditope and thanks for your exceptional effort. Have filed for repeated reference. Well done !

https://endpts.com/german-cancer-biotech-biontech-raises-a-mammoth-325m-in-latest-round-bringing-total-haul-to-1-4b/

Hey Moljen no problem - by default, we get an implied mention ! BioNTech have . . . '' a string of key partnerships with titans of the pharmaceutical industry''.

Now one must be Scancell (wink). Here's 'Endpoints' :-

hTTps://endpts.com/german-cancer-biotech-biontech-raises-a-mammoth-325m-in-latest-round-bringing-total-haul-to-1-4b/

Berm spotted this in the FT - here it is in FierceB. That's the way to do it!

''BioNTech has raised $325 million (€289 million) in a private fundraising round. The series B positions the immuno-oncology player to advance its multidrug clinical pipeline and grow its manufacturing footprint.

Mainz, Germany-based BioNTech operated for a decade without raising a headline-grabbing round, opting instead to run on money from its billionaire majority owners and partnership fees, such as the $310 million in upfront and near-term milestones put up by Genentech. That changed early in 2018 when BioNTech raised $270 million in a Redmile Group-led series A round.

Now, BioNTech has raised $325 million in a round led by Fidelity Management & Research Company. Other existing investors including Redmile and the Struengmann Family Office contributed to the series B round, but two-thirds of the cash came from new investors.''

hTTps://www.fiercebiotech.com/biotech/biontech-raises-325m-b-round-to-advance-cancer-pipeline?utm_source=internal&utm_medium=rss

WF - Jeffrey Bluestone ?
''Jeffrey Bluestone, the pioneering immunologist at the University of California, San Francisco, who Parker picked to lead PICI as president and CEO.'' ??

Crumbs - a late response to yesterday 09.23 re. Juno and Kite. Thanks. I wonder how those $9 and $11 bn stand up against sales so far ? We used to discuss Innovio a lot too - I wonder how they're doing ?
GLA

I wonder how Kite and Juno are faring now after those lofty deals ?

The Graham Threader case reminded me of this . . .

https://www.fiercebiotech.com/r-d/juno-ditches-lead-car-t-program-following-patient-deaths

Chester - ''Just shows how much a successful MODI platform is so needed..'' and Crumbs ''Come on team scancell ....'' Yes indeed !

From a report in today's DT :-

''. . . he was told that the CAR T trial was about to start, and that he was eligible to join. “We said yes at once,” says Mellie. “Regardless of the dangers, it was clear that it was still the only hope we had.” It took several months for Graham’s CAR T cells to be ready for use (the untreated T cells were donated by his brother). Then in January 2018, the therapy began.''

hTTps://www.telegraph.co.uk/health-fitness/body/husband-died-trialling-radical-new-cancer-cure-now-sacrifice/

This recent update appears in PM Live's page hTTp://www.pmlive.com/pharma_news/scancell_preps_phase_2_challenge_for_melanoma_vaccine_1292923

Much the same as other releases I guess - anyway - nice day all.

Tks for that DA & Ruck, RP. Had some busy weeks having fun in UK - back to Th next week. GLA

Takestock - obviously there IS no deal atm. Whether there is a deal coming - we just don't know.

Knowlesi - ''I felt the lack of mention in the RNS didn't perhaps bode well.'' It's quite reasonable to argue the opposite - it being unlikely Scancell that will advise us until it happens - if it is to happen that is . . . .

''Looks like this is the title of the SCIB1 trial:-

'A phase 2, multicentre, open-label study of SCIB1 in patients with advanced unresectable melanoma receiving pembrolizumab'

Am sure we're all going to know it by heart within a few weeks.''

C7 it's not like you to miss the RNS !

I was just about to post this bit as you have extracted, ''it is proposed that Martin Diggle of Vulpes is appointed to the Board as a Non-Executive Director.''

Excellent news and as observed by Berm, we will now have a Non-Exec whose interests align ? Good link RW - Martin Diggle is an operator on the inside track ?

5p - well done CH but a steal nevertheless. GLA

" "Scancell, the developer of novel immunotherapies for the treatment of cancer, today announces that it has raised gross proceeds of £3,877,965.55 by the issue of 77,559,311 new ordinary shares ("Subscription Shares") at a price of 5 pence per share (the "Subscription") to Vulpes Life Sciences Fund ("Vulpes") under existing shareholder authorities. . . . . .

Vulpes Investment Management was founded in 2011 by Stephen and Martin Diggle and is designed to enable outside co-investment in a range of strategies that seek to produce real capital appreciation and income by concentrating on a small number of compelling investment opportunities. Vulpes Investment Management established the Vulpes Life Sciences Fund in 2012

(Martin Diggle) "I am very pleased to be investing in Scancell at this exciting time in the company's evolution. Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time. We have concluded the company's unique and innovative approach to fighting cancer is compelling and under-appreciated. At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly." "

16.67 % - the major shareholder now. Well done CH ? IMO good news . . . .

Thanks WF - approaching 40 times Scancells MCap ? MMMmmmmm.

Keith Flaherty chatting Melanoma on this link, Jennifer Wargo too.

https://www.massgeneral.org/about/news/multimedia.aspx?id=618

''AstraZeneca will continue to look for ‘transformational’ drugs to add to its oncology portfolio, as it sharpens its focus under new cancer R&D chief José Baselga. Earlier this year the drug maker paid $1.36bn (£1.07bn) to work with Japanese pharmaceutical company Daiichi Sankyo on a promising breast cancer treatment, with a further $5.54bn to be paid to Daiichi if the drug achieves certain milestones. The size of the deal raised eyebrows among some analysts who worry about AstraZeneca’s growing debt pile and ability to make generous dividend payments to shareholders.''

Anyone any ideas where they could look ?????

https://www.telegraph.co.uk/business/2019/06/11/astrazeneca-still-hunt-transformational-cancer-drug-deals/